2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Infusion, Adverse Events, Clinical Practice (Health Services and Quality), Quality Improvement, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, B Cell Lymphoma, Research, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly
PAPER

2417 Impact of pirtobrutinib on the manufacturing and functionality of dual targeted lentiviral anti-CD20, anti-CD19 (LV20.19) CAR T cells

Farah Yassine, MD, MSc, Fateeha Furqan, MBBS2, Kaitlin Annunzio, MD3, Gulrayz Ahmed, MD4, Tyce Kearl, MD, PhD5, Bryon Johnson, PhD6, Peiman Hematti, MD7, Walter Longo, MD8, Mehdi Hamadani, MD9, Nirav N. Shah, MD, MS10
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Introduction:

Combination trials of BTK inhibitors (BTKi) with chimeric antigen receptor (CAR) T cell therapy have suggested potential synergistic benefits by improving CAR T immunophenotype and clinical outcomes, but prospective data are limited. Pirtobrutinib (pirto) is a highly selective non-covalent BTKi with activity across B cell malignancies and currently FDA approved for relapsed, refractory (R/R) mantle cell lymphoma (MCL) and R/R chronic lymphocytic leukemia after prior covalent BTKi-containing therapy. Our group previously reported that pirto bridging prior to LV20.19 CAR T cells may improve product functionality and clinical outcomes in R/R B cell lymphoma (Furqan et al. ASCO 2024). To better understand the impact of pirto on LV20.19 CAR T cells, we developed a phase 1 clinical trial using pirto as a mandatory bridge to LV20.19 manufacturing and as maintenance post CAR T infusion (NCT05990465). We present the initial translational data on the impact of pirto bridging on LV20.19 CAR T cell manufacturing and product functionality.

 

Methods:

In this phase 1 trial, patients with R/R B cell malignancies received pirto bridging and maintenance with LV20.19 CAR T cells at a fixed dose of 2.5e6 cells/kg. LV20.19 CAR T cells were manufactured on-site using an adaptive 8/12-day process with the CliniMACS Prodigy® device. To enable a fresh infusion, lymphodepletion (LDP) with fludarabine and cyclophosphamide was initiated during the manufacturing process. Pirto, at daily oral dose of 200mg, was mandated as a bridge therapy for a minimum of 14 days before apheresis and continued until initiation of LDP. Patients with stable disease, partial response, or complete response at day 28 post LV20.19 CAR T were eligible to restart pirto maintenance for up to 12 cycles.

We describe the immunophenotype of the apheresis product, final LV20.19 CAR T cell product, and single cell cytokine secretion after pirto exposure. To understand the impact of pirto on LV20.19 CAR T cell manufacturing and functionality, we compared final products to a cohort of LV20.19 CAR T cell products manufactured under similar conditions in a prior clinical trial (NCT04186520) without pirto exposure.

 

Results:

To date, 10 patients with R/R B cell malignancies (Diffuse Large B cell Lymphoma=7, Follicular Lymphoma=2, MCL=1) are enrolled. Nine patients received pirto for a minimum of 14 days followed by apheresis for manufacturing of LV20.19 CAR T cells. One patient was rendered ineligible after CNS progression three days into pirto bridging and was taken off trial. All 9 patients achieved the target cell dose of 2.5e6 cells/kg after 8 days of manufacturing. Median transduction efficiency was 26.2% (range 14.9% - 31.9%).

 

The nine pirto-exposed LV20.19 CAR products were compared with 46 LV20.19 CAR products from pirto-naïve patients. In apheresis products, flow cytometry of differentiation markers revealed no differences between more naïve (stem cell-memory/naïve/central-memory) or more differentiated (effector-memory RA+/effector-memory) T cell subsets between pirto-exposed versus unexposed cohorts. Similarly, final LV20.19 products did not show differences in the differentiation markers. Interestingly, after analysis of cells with a panel of T cell activation markers, there were more CD25+CD4+ and CD25+CD8+ T cells in the final LV20.19 product from pirto-exposed patients versus unexposed (p=0.017 and p=0.038 respectively). Similarly, there were more CD137+CD8+ LV20.19 CAR T cells in the pirto-exposed cohort (p=0.019). There were no differences in activation marker expression for apheresis product, nor in the expression of T cell proliferation markers in either apheresis or final products. Finally, the polyfunctional strength index and polyfunctionality of the final LV20.19 products did not differ by pirto-exposure.

 

Conclusions:

Pirto bridging had no detrimental impact on LV20.19 CAR T cell manufacturing. All patients achieved successful manufacturing within 8 days, consistent with rapid ex-vivo expansion. Pirto exposure prior to apheresis was associated with enhanced CAR T activation phenotype in the final LV20.19 product (increased CD137/CD25 expression) without impacting the differentiation profile or polyfunctionality. This suggests a potential synergistic relationship. Clinical accrual is ongoing and outcomes will be reported with adequate follow-up.

Farah Yassine, MD, MSc: No relevant conflicts of interest to declare.